Palisade Bio, Inc. (PALI) stock
Close on Nov 12, 2026Market cap $198.67MP/E –Yield –
Palisade Bio, Inc. reported revenue of $500.00K for the twelve months to Sep 30, 2026. At the latest close the market valued the company at $198.67M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $198.67M
- P/E ratio
- –
- Price to sales
- 397.34
- Price to book
- 1.77
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $500.00K
- Net income
- -$43.70M
- EPS, diluted
- -$0.30
- Book value per share
- $0.53
- Diluted shares
- 212M
Trading
- Previous close
- $1.17
- Open
- $1.16
- Day's range
- $1.13 – $1.18
- Volume
- 985,371
- Average volume (20 days)
- 3,860,768
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.97
- 52-week range
- $1.08 – $2.85
- RSI (14 days)
- 38.2
- Volatility (1 year)
- 89.8%
- Relative volume
- 0.34×
- WACC
- 9.7%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PALI | S&P 500 | Difference | PALI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.3% | -2.7% | −25.6 pts | ||
| 3 months | -41.8% | -1.7% | −40.1 pts | ||
| Year to date | -51.5% | +11.9% | −63.4 pts | ||
| 1 year | -44.1% | +12.0% | −56.1 pts | ||
| 3 years | -85.7% | +78.2% | −163.8 pts | -47.7% | +21.2% |
| 5 years | -99.9% | +73.2% | −173.2 pts | -77.6% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -71.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Palisade Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- News
About Palisade Bio
Biological Products, (No Diagnostic Substances)
The company is a clinical-stage biopharmaceutical business focused on developing oral phosphodiesterase-4 inhibitor prodrugs for inflammatory and fibrotic diseases. Its primary product candidate, PALI-2108, is an orally delivered therapy engineered for targeted bacterial bioactivation in the lower gastrointestinal tract. Alongside its therapeutic candidates, the business develops biomarker assays to identify individuals who are likely to respond to treatment. Its target patient populations consist of individuals suffering from inflammatory bowel diseases, specifically ulcerative colitis and Crohn's disease, including fibrostenosing Crohn's disease.
Company profile, executives and historyPalisade Bio stock: common questions
What is Palisade Bio's stock price?
PALI closed at $1.14 on Nov 12, 2026, down 2.56% on the day. Over the past 52 weeks it traded between $1.08 and $2.85.
What is Palisade Bio's market cap?
Palisade Bio was worth $198.67M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PALI's P/E ratio?
Palisade Bio lost money over fiscal 2025 (diluted EPS -$0.30), so it has no meaningful P/E ratio.
How much revenue does Palisade Bio make?
Palisade Bio reported revenue of $500.00K for the twelve months to Sep 30, 2026.
Does Palisade Bio pay a dividend?
No. Palisade Bio has not paid a cash dividend over the last twelve months.
How has PALI stock performed over the past year?
Including dividends, PALI returned -44.1% over the past year, against +12.0% for the S&P 500.
How many PALI shares are sold short?
29M shares were sold short at the latest FINRA report, 17.63% of the float, or 7.8 days of average trading volume.
Who are Palisade Bio's competitors?
Companies most similar to Palisade Bio by business, industry and size include CRDF, YARW, IMA, CMPX, SRRK.
See a number that looks wrong?